Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) today reported financial and operating results for the second quarter 2006. The Company had a net loss in the quarter of $6.9 million, which includes a stock-based compensation expense of $2.1 million. At the end of the second quarter 2006, the Company had $65.0 million in cash, cash equivalents and marketable securities, which include the proceeds from a $45.3 million private placement with several institutional investors completed in April.
